MedPath

STEP-IT-UP - Peanut Allergy Study for Infants

Phase 2
Withdrawn
Conditions
Peanut Allergy
Food Allergy
Interventions
Biological: Peanut powder or peanut butter
Registration Number
NCT04761835
Lead Sponsor
Johns Hopkins University
Brief Summary

Multicenter randomized (1:1) trial of strict avoidance versus sub-threshold dietary introduction of peanut in peanut allergic infants 4-14 months of age who react at a minimum cumulative dose of at least 430 mg of peanut protein at initial oral food challenge (OFC) for 12 months, followed by cross-over to sub-threshold dietary introduction of peanut in those randomized initially to avoidance.

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Children age 4-14 months suspected to be peanut allergic
Exclusion Criteria
  • Significant medical problems

Study & Design

Study Type
INTERVENTIONAL
Study Design
SEQUENTIAL
Arm && Interventions
GroupInterventionDescription
Dietary PeanutPeanut powder or peanut butterParticipants in this group will be asked to continue peanut in their diet for 1 year at a dose determined from the double blind placebo controlled food challenge at baseline. After the 1 year period, participants will be given another double blind placebo controlled food challenge which will be used to determine their current peanut threshold. The current peanut threshold will be used to determine which participants will go into clinical care and which will get sustained unresponsiveness food challenges to peanut.
Primary Outcome Measures
NameTimeMethod
Oral food challenge threshold to peanut at week 5252 weeks

compare the oral food challenge threshold (in milligrams) to peanut during a double-blind placebo-controlled food challenge (DBPCFC) after 12 months between subjects randomized to dietary peanut introduction and those randomized to avoidance.

Secondary Outcome Measures
NameTimeMethod
Rate of discontinuation of dietary peanut104 weeks

Number of participants randomized to dietary peanut who discontinue peanut.

Peanut skin prick test wheal size104 weeks

Average wheal size (millimeters) of peanut skin prick test for participants in each group.

Severity of eczema as assessed by the Scoring Atopic Dermatitis (SCORAD) score104 weeks

Eczema severity as assessed by the SCORAD. The SCORAD has a component for patient measured outcomes and also provider assessment of eczema involvement. It has an overall score range of 0-100, where higher scores signify more severe eczema.

1. Oral food challenge threshold to peanut at week 52 for those initially randomized to dietary peanut compared to the oral food challenge threshold at week 104 for those initially randomized to strict avoidance104 weeks

Compare the oral food challenge threshold (in milligrams) to peanut during a double-blind placebo-controlled food challenge (DBPCFC) after 12 months of dietary peanut between subjects randomized to dietary peanut introduction first and those randomized to avoidance for 52 weeks and subsequent dietary peanut after week 52.

Oral food challenge threshold at 1 month avoidance after 12 months in each treatment group56 weeks

Comparison of OFC threshold (in milligrams) at 1 month of avoidance (sustained unresponsiveness) after 12 months of dietary peanut between those initially randomized to peanut and those randomized to delayed introduction.

Oral food challenge threshold at 2 months avoidance after 12 months in each treatment group60 weeks

Comparison of OFC threshold (in milligrams) at 2 months of avoidance (sustained unresponsiveness) after 12 months of dietary peanut between those initially randomized to peanut and those randomized to delayed introduction.

Safety with dietary introduction of peanut or avoidance52 weeks

Number of participants who have severe (grade 3) anaphylaxis secondary to any DBPCFC or ingestion of the measured dose of peanut.

© Copyright 2025. All Rights Reserved by MedPath